01. Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed

Permanent URI for this communityhttps://hdl.handle.net/20.500.14365/1

Browse

Browsing 01. Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed by Subject "(18)FDG-PET/CT"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Article
    Evaluation of Response To Gemcitabine Plus Cisplatin-Based Chemotherapy Using Positron Emission Computed Tomography for Metastatic Bladder Cancer
    (Baishideng Publishing Group Inc, 2023) Öztürk, Hakan; Karapolat, İnanç
    BACKGROUNDThe purpose of the present study was to examine retrospectively the contribution of (18)Fluorodeoxyglucose positron emission tomography computed tomography ((18)FDG-PET/CT) to the evaluation of response to first-line gemcitabine plus cisplatin-based chemotherapy in patients with metastatic bladder cancer. AIMTo evaluate the response to Gemcitabine plus Cisplatin -based chemotherapy using (18)FDG-PET/CT imaging in patients with metastatic bladder cancer. METHODSBetween July 2007 and April 2019, 79 patients underwent (18)FDG-PET/CT imaging with the diagnosis of Metastatic Bladder Carcinoma (M-BCa). A total of 42 patients (38 male, 4 female) were included in the study, and all had been administered Gemcitabine plus Cisplatin-based chemotherapy. After completion of the therapy, the patients underwent a repeat (18)FDG-PET/CT scan and the results were compared with the PET/CT findings before chemotherapy according to European Organisation for the Research and treatment of cancer criteria. Mean age was 66.1 years and standard deviation was 10.7 years (range: 41-84 years). RESULTSOf the patients, seven (16.6%) were in complete remission, 17 (40.5%) were in partial remission, six (14.3%) had a stable disease, and 12 (28.6%) had a progressive disease. The overall response rate was 57.1 percent. CONCLUSION(18)FDG-PET/CT can be considered as a successful imaging tool in evaluating response to first-line chemotherapy for metastatic bladder cancer. Anatomical and functional data obtained from PET/CT scans may be useful in the planning of secondline and thirdline chemotherapy.